other material
confidence high
sentiment positive
materiality 0.65
Revolution Medicines reports positive clinical data for RMC-6236 and RMC-6291; selects RMC-5127
Revolution Medicines, Inc.
- RMC-6236 shows acceptable safety in 131 patients; common TRAEs include rash (70%) and GI toxicities, mostly Grade 1-2.
- RMC-6236 demonstrates dose-dependent exposure and ctDNA reductions across NSCLC, PDAC, and multiple KRAS mutations.
- RMC-6291 achieves 50% ORR in NSCLC (prior G12Ci) and 43% in G12Ci-naïve; 40% ORR in CRC with 80% DCR.
- RMC-6291 safety includes 25% QTc prolongation (11% Grade 3) but no cardiac sequelae or hepatotoxicity signal.
- RMC-5127, an oral covalent tri-complex inhibitor of KRAS G12V (ON), selected as a development candidate.